Credit rating agency, CRISIL has upgraded the rating of long-term bank facilities of Alembic Pharmaceuticals to ‘AA+/Stable’ from ‘AA/Positive’ worth Rs 315 crore limit of fund/non-fund based facilities.
Moreover, the rating agency has reaffirmed the rating of the company's short-term debt including Commercial Paper to ‘A1+’ worth Rs 200 crore.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
